HomeCompareMOPHY vs MRK

MOPHY vs MRK: Dividend Comparison 2026

MOPHY yields 3.11% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MOPHY wins by $37.3K in total portfolio value· pulled ahead in Year 4
10 years
MOPHY
MOPHY
● Live price
3.11%
Share price
$17.16
Annual div
$0.53
5Y div CAGR
39.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$95.0K
Annual income
$29,243.08
Full MOPHY calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — MOPHY vs MRK

📍 MOPHY pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMOPHYMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MOPHY + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MOPHY pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MOPHY
Annual income on $10K today (after 15% tax)
$264.56/yr
After 10yr DRIP, annual income (after tax)
$24,856.62/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MOPHY beats the other by $16,259.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MOPHY + MRK for your $10,000?

MOPHY: 50%MRK: 50%
100% MRK50/50100% MOPHY
Portfolio after 10yr
$76.4K
Annual income
$19,678.43/yr
Blended yield
25.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

MOPHY
No analyst data
Price Target
$15.75
-8.2% upside vs current
Range: $15.75 — $15.75
Altman Z
8.0
Piotroski
6/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MOPHY buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMOPHYMRK
Forward yield3.11%2.81%
Annual dividend / share$0.53$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR39.6%32.7%
Portfolio after 10y$95.0K$57.7K
Annual income after 10y$29,243.08$10,113.78
Total dividends collected$67.8K$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst price target$15.75$128.54

Year-by-year: MOPHY vs MRK ($10,000, DRIP)

YearMOPHY PortfolioMOPHY Income/yrMRK PortfolioMRK Income/yrGap
1$11,135$434.51$11,213$373.04$78.00MRK
2$12,545$631.21$12,667$512.06$122.00MRK
3$14,351$927.85$14,439$708.14$88.00MRK
4← crossover$16,741$1,384.81$16,640$988.16+$101.00MOPHY
5$20,020$2,107.53$19,432$1,394.07+$588.00MOPHY
6$24,710$3,288.28$23,057$1,992.90+$1.7KMOPHY
7$31,734$5,295.10$27,889$2,894.79+$3.8KMOPHY
8$42,828$8,872.37$34,518$4,286.29+$8.3KMOPHY
9$61,448$15,622.16$43,912$6,494.35+$17.5KMOPHY
10$94,993$29,243.08$57,714$10,113.78+$37.3KMOPHY

MOPHY vs MRK: Complete Analysis 2026

MOPHYStock

Monadelphous Group Limited, an engineering group, provides construction, maintenance, and industrial services to resources, energy, and infrastructure industries in Australia, Chile, Mongolia, China, Papua New Guinea, and internationally. It operates through Engineering Construction, and Maintenance and Industrial Services divisions. The company offers fabrication, modularization, offsite pre-assembly, procurement, and installation of structural steel, tankage, mechanical and process equipment, piping, demolition, and remediation works; multi-disciplined construction services; plant commissioning; electrical and instrumentation services; engineering, procurement, and construction services; process and non-process maintenance services; and front-end scoping, shutdown planning, management, and execution services. It also provides water and wastewater asset construction and maintenance; transmission pipelines and facilities construction; power and water assets operation and maintenance; heavy lift and specialist transport; access solutions; dewatering services; corrosion management services; specialist coatings; rail maintenance services; and insulation and cladding services. In addition, it offers turnkey design and construction, heavy lift and crane, and civil and electrical services. Monadelphous Group Limited was founded in 1972 and is headquartered in Perth, Australia.

Full MOPHY Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this MOPHY vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MOPHY vs SCHDMOPHY vs JEPIMOPHY vs OMOPHY vs KOMOPHY vs MAINMOPHY vs JNJMOPHY vs ABBVMOPHY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.